Record number of patent infringement actions filed in 2011, says PwC US
The number of patent infringement actions filed in 2011 reached 4,015 – the highest number ever recorded, according to data compiled in the 2012 Patent Litigation Study released last week by PricewaterhouseCoopers (PwC) US.
In 2011, there was a 22% increase in the number of filings over 2010, and an overall compound annual growth rate (CAGR) of 6.4% since 1991. PwC's 2012 Patent Litigation Study notes that courts have been applying greater scrutiny to damages assessments in patent infringement matters – a trend expected to continue.
Annual median damages awards have ranged from $1.9 million to $16.1 million between 1995 and 2011. More recently, from 2006-2011, the median damages award has been around $4.0 million. In 2012, two of the four largest patent infringement damages amounts were awarded – totaling approximately $1 billion in damages each.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze